A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy

Trial Profile

A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Macimorelin (Primary)
  • Indications Growth disorders
  • Focus Diagnostic use; Registrational
  • Sponsors AEterna Zentaris Inc; Ardana plc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Nov 2013 New trial record
    • 05 Nov 2013 Data from this trial have been included in an NDA submitted to the FDA for the use of macimorelin in the diagnosis of adult growth hormone deficiency, according to an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top